FibroGen Inc (NAS:FGEN)
$ 1.13 0.03 (2.73%) Market Cap: 112.41 Mil Enterprise Value: 84.76 Mil PE Ratio: 0 PB Ratio: 0 GF Score: 56/100

Q4 2023 FibroGen Inc Earnings Call Transcript

Feb 26, 2024 / 10:00PM GMT
Release Date Price: $1.85 (+1.65%)
Operator

Thank you for standing by, and welcome to FibroGen's Fourth Quarter and Full Year 2023 Earnings Conference Call. (Operator Instructions) Please be advised that today's call is being recorded.

I would like to turn the call over to your host, Mr. David DeLucia, Vice President of Investor Relations. Please go ahead.

David DeLucia
FibroGen, Inc. - VP of Corporate FP&A and IR

Good afternoon, everyone. Thank you for joining today to discuss our fourth quarter and year-end 2023 financial and business results. I'm David DeLucia, Vice President of Corporate FP&A and Investor Relations at FibroGen.

Joining me on today's call are Thane Wettig, our Chief Executive Officer; Juan Graham, our Chief Financial Officer; Dr. John Hunter, our Chief Scientific Officer; and Chris Chung, our Senior Vice President of China Operations.

Following our prepared remarks, we will open the call to your questions. I would like to remind you that remarks made on today's call include forward-looking statements about FibroGen. Such statements may include,

Already have an account? Log in
Get the full story
Access to All Earning Calls and Stock Analysis
30-Year Financial on one screen
All-in-one Stock Screener with unlimited filters
Customizable Stock Dashboard
Real Time Insider Trading Transactions
8,000+ Institutional investors’ 13F holdings
Powerful Excel Add-in and Google sheets Add-on
All data downloadable
Quick customer support
And much more...
30-Day 100% money back guarantee
You are not charged until the trial ends. Subscription fee may be tax deductible.
Excellent
4.6 out of 5 Trustpilot